Implementing tighter intensity modulated radiation therapy (IMRT) quality assurance (QA) tolerances initially resulted in high numbers of marginal or failing QA results and motivated a number of improvements to our calculational processes. This work details those improvements and their effect on results. One hundred eighty IMRT plans analyzed previously were collected and new gamma criteria were applied and compared to the original results. The results were used to obtain an estimate for the number of plans that would require additional dose volume histogram (DVH)-based analysis and therefore predicted workload increase. For 2 months and 133 plans, the established criteria were continued while the new criteria were applied and tracked in parallel.
| INTRODUCTION
The clinical relevance of intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) quality assurance (QA; further referred to as IMRT QA) is often questioned [1] [2] [3] [4] due to the lack of sensitivity of the IMRT QA methods. Recent recommendations 5 and publications 6 
| MATERIALS AND METHODS

2.A | Retrospective IMRT QA analysis
One hundred eighty plans, 101 head and neck and 79 prostate VMAT/IMRT (further referred to as IMRT) plans analyzed in the preceding year were collected. All plans had been planned using version Corp., USA) using the gamma criteria 7 of 3%/3 mm, global and 10% threshold (The software switch "Apply measurement uncertainty" was on, so the criteria correlates with 4%/3 mm with uncertainty correction off). A passing threshold of 92% had been used for many years, and all these plans had passed. The plans were reanalyzed with the new gamma criteria of 3%/2 mm, global, 10% threshold, and uncertainty corrections off, and the plans were binned into the categories of "pass" (>95% of diodes passing), "questionable" (between 90% and 95%), and "failed" (<90%). 6 The results using the new criteria were used to obtain an estimate for the number of plans requiring additional dose volume histogram (DVH)-based analysis using 3DVH software (Sun Nuclear Corp., USA) and therefore the predicted workload increase. There was an observed increased frequency of problematic plans once all IMRT QA were included in the new analysis method (see Table 1 below). DVH analysis demonstrated that over 50% of the problematic plans were measuring cold in the organs at risk (OAR) and hot in the planning target volume (PTV), which indicated that there was a systematic difference between the TPS and resulting treatment. This motivated a series of investigations and modifications to our processes in order to reduce the effects of systematic calculational artifacts. These are detailed below. Subsequent to these changes, the new criteria were clinically implemented. The distribution of IMRT QA results between "pass," "questionable," and "fail"
was analyzed for the next 673 plans over 15 months. T A B L E 1 Distributions of pass, questionable, and failed plans for the retrospective analysis of H & N and prostate IMRT quality assurance (QA) measurements, the first 2 months of clinical testing prior to introducing the calculational changes, and the subsequent 15 months of IMRT QA measurements. The gamma criteria are 3%/ 2 mm, 10% threshold with >95% of points passing being a pass, between 90% and 95% being questionable and below 90% being a fail. 
Pass
2.B.2 | QA phantom calibration
The model for the ArcCHECK phantom within Eclipse was checked to ensure the correct bulk density was assigned and the model was correct as defined by Sun Nuclear. The calibration routine and the dose calibration factor were retaken to ensure that the ArcCHECK was calibrated correctly for each LINAC it was used on. Simple fields (e.g., parallel opposed 10 × 10 cm) were measured and compared to the TPS to ensure that there was agreement between the two for simple cases. 
2.B.3 | DLG & leaf transmission settings
2.B.4 | Couch top model values
Due to a discrepancy seen between the TPS and the corresponding ArcCHECK measurement for a 360°open field arc (see Fig. 2 below) and that this same phenomenon was not observed with a 180°arc avoiding the table, it was determined that couch top model being used was inadequate.
AAPM TG-176 8 was used to define the attenuation of the couch top through multiple angles and arc lengths. Ideally a cylindrical phantom is available to make complementary angle measurements redundant; however, a cylindrical phantom was unavailable. Therefore, measurements were taken using a slab phantom as described in TG-176 8 as the alternate approach and depicted in Fig. 3 . Measurements were taken with an ion chamber through the couch into the F I G . 1. Eclipse calculated 1 mm grid displayed in purple and Eclipse calculated 2.5 mm grid interpolated to 1 mm by SNC displayed in black.
ArcCHECK measurement results of a 360°open arc, including transmission through the couch, compared to the TPS calculation of the same arc. Cold spots occur at~240°and~130°which correspond to the thickest portion of the couch. Eclipse models the couch top via an inner and outer surface.
These two variables were iterated to minimize the error for the various angles and arcs measured. The geometry of these models are fixed and hardcoded in Eclipse.
The combined effect of changing the grid size and improving the couch model was tested using 15 single isocenter multiple metastases SRS cases. These were chosen because the effect of grid size would be more important for these plans. impact on the measurement results, especially for small field plans as can be seen in Fig. 7 . In this case, the 3%/2 mm passing rate for the plan increased from 90.1% to 96.8% by changing the DCF angular resolution setting. The gamma results for larger field plans also were impacted, although not as drastically (~2% increase) as small fields as can be seen in Table 2 .
Couch modeling and dose grid results
The original couch models demonstrated up to a 4.2% difference between the TPS and the corresponding measurement for select beam directions. After optimizing the surface and interior HU values for the couch in Eclipse, the error between the TPS plan and measurement decreased to less than 0.5%. Table 3 demonstrates the average gamma passing rate of all 15 SRS plans along with their standard deviation as the grid increment was reduced and, finally, the improved couch model assigned.
3.B.2 | DLG & leaf transmission settings
After iterating through four different DLG/transmission factors, it was found that for 6 MV, changing the DLG from 0.24 cm to 0.21 cm and changing the transmission factor from 0.015 to 0.017, increased the gamma passing rates for all plans measured. This was true for both the Clinac and TrueBeam and decreased the maximum difference between gamma passing rates for the two machines from 6% to 4.8% (Table 4) .
For 18 MV, it was found that changing the DLG from 0.1817 to 0.2 cm and keeping the transmission factor at 0.0152 gave the most optimal results. This increased the passing rate for all plans measured on the Clinac. When the plans were measured on the TrueBeam, half saw an increase in gamma passing rate while the other half saw a slight decrease in gamma passing rate. However, the maximum percent gamma passing rate difference between the Clinac and TrueBeam decreased from 7.6% to 3.5% (Table 4) . have completely transitioned to the newer machines and will adjust the models accordingly.
| DISCUSSION
| CONCLUSION S
Tightening IMRT QA tolerances revealed the need to improve several elements of our IMRT and VMAT calculations. As a consequence, the accuracy of our treatment planning has improved, and the frequency of finding marginal or failing IMRT QA results, while much larger than before the tightening, remains within our practical ability to respond.
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